RT Journal Article
SR Electronic
T1 Long-term neurological and gastrointestinal sequelae of SARS-CoV-2, influenza, and other neurotropic infections with and without vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.25.24310990
DO 10.1101/2024.07.25.24310990
A1 Konings, Bo
A1 Villatoro, Luisa
A1 Burns, Robert
A1 Barahona, Guillermo
A1 McKnight, Megan
A1 Hui, Ken
A1 Tack, Jan
A1 Pasricha, Pankaj Jay
YR 2024
UL http://medrxiv.org/content/early/2024/07/26/2024.07.25.24310990.abstract
AB COVID-19 increases the risk of neurological and gastrointestinal sequelae, but it is unclear if it does so more than other infections. Using a multicenter record network, we matched 649,478 COVID-19 patients to negative controls (NCs) and patients infected with influenza, human herpesvirusses, and lyme’s disease (LD) to compare new-onset gastrointestinal (GISx), autonomic (ANSx), sensory (SNSx), and motor (MNSx) symptoms 3-12 months after infection. ANSx showed significant increases compared to NCs (odds ratio (OR) 1.34; confidence interval (CI) 1.31-1.36) and most other investigated infections (LD, influenza, infectious mononucleosis, and herpes zoster; OR 1.40, 1.13, 1.11, and 1.05, respectively). SNSx (OR 1.35; CI 1.31-1.39), MNSx (OR 1.32; CI 1.28-1.36) and GISx (OR 1.36; CI 1.33-1.38) were increased but varied more compared with other infections. COVID-19 vaccination reduced the risk of GISx, ANSx, and SNSx. Sequelae frequently ascribed to COVID-19 may manifest with similar or higher frequency after other infections, except ANSx.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Johns Hopkins Medicine Institutional Review Boards (IRB) have exempted this study from IRB review, as it involves aggregated and de-identified medical record data which is not considered human subjects research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData were exported from TriNetX in .csv files and archived. Every (co-) author affiliated to Johns Hopkins University was granted access to the TriNetX Research network by the Institute of Clinical and Translational Research (ICTR). The supplementary materials contain an extensive list of tables representing the original data; researchers will be granted access to the original data for specific concerns upon approval from the corresponding author (PJP).